Edwards Lifesciences: Minimally Invasive Valve Procedure Shows Lower Mortality in Trial

What happened

The investigator-initiated SURVIV trial, presented at the American College of Cardiology's Annual Scientific Session, enrolled 150 patients (average age 58, 72% women) across seven centers in Brazil who needed mitral valve replacement due to deteriorating bioprosthetic valves. Patients were randomly assigned to receive either a transcatheter mitral valve-in-valve procedure or standard repeat open-heart surgery. All valves used in the transcatheter arm were manufactured and donated by Edwards Lifesciences. At one year, the primary endpoint of death or disabling stroke occurred in 5.3% of transcatheter patients versus 20.8% of surgical patients. The transcatheter group experienced no in-hospital deaths compared to 12.5% in the surgery group, and had significantly fewer major bleeding events and kidney injury complications. Patients also left the hospital faster (median 4 vs. 14 days). However, the surgery group showed better valve performance over time, with lower mean mitral gradients and larger valve areas by 12 months, and fewer cardiac-related rehospitalizations.

Why it matters

This is the first randomized trial directly comparing transcatheter mitral valve-in-valve procedures to repeat surgical replacement, providing clinical evidence for a less invasive alternative for high-risk patients. Edwards Lifesciences manufactures the transcatheter valves used in the study, and positive trial results could support broader adoption of its device in patients with failing bioprosthetic mitral valves. The findings are particularly significant given that up to 30% of patients need repeat mitral valve replacement after about 10 years, and redo surgeries carry mortality risks of approximately 7% compared to less than 1% for initial replacements. However, surgery still showed superior valve performance metrics at one year. The trial population consisted largely of younger patients with rheumatic valve disease common in middle- and low-income countries, which differs from typical U.S. patient profiles where repeat procedures occur in older populations.

Bigger picture

The results come as bioprosthetic valve replacement has increased over recent decades, creating a growing population requiring repeat interventions. Multiple surgeons and cardiologists commenting on the trial emphasized the importance of individualized heart team decisions, noting that factors such as patient age, comorbidities, and previously implanted valve size influence optimal treatment selection. While U.S. patients typically undergo first mitral valve surgery around age 64, in regions with prevalent rheumatic disease patients often require their first surgery in their 30s or 40s, necessitating repeat procedures a decade later. Some experts expressed surprise at the surgical group's mortality rate and questioned whether concomitant procedures in some patients affected outcomes. Long-term durability of the transcatheter approach remains uncertain, with ongoing 10-year follow-up planned. Concerns about potential valve thrombosis in the mitral position, which has lower blood flow velocities than the aortic position, require further investigation.

What to watch

Investors should monitor the ongoing 10-year follow-up data from SURVIV to assess long-term durability and valve performance of Edwards' transcatheter mitral valve-in-valve device. Key metrics include whether survival curves eventually favor surgery and whether hemodynamic differences widen over time. Watch for additional data on subclinical valve thrombosis through planned serial CT evaluations at baseline, 3 months, and 12 months. The evolving composition of patients referred for transcatheter versus surgical approaches, particularly regarding age, risk profile, and previous valve size, will influence market adoption. Regulatory decisions and guideline updates following this first randomized evidence in the space could also impact treatment patterns. Finally, whether similar results hold in different patient populations, particularly older patients with degenerative valve disease more common in developed markets, remains to be seen.

This article was generated by Quantli AI using publicly available news sources.